About CJC-1295 Ipamorelin: an observational reading of the record

What this site is

CJC Ipa Peptide is an observational field notebook that reads the peer-reviewed literature on the CJC-1295 + ipamorelin pairing in plain English. No clinic keeps it and no clinician writes in it; it gives no medical advice, makes no product, and sells nothing. It reads the GH-axis literature carefully and cites everything it claims — that is the whole of the entry.

The approach is deliberately observational, matching the name: each half of the stack is read against its own studies, every quantitative claim is pinned to a source, and the gaps — chiefly that the fixed blend has never been studied in a controlled human trial — are left in plain sight rather than smoothed over.

What the name does and does not mean

The domain pairs two compound names because the subject is a two-peptide research combination — not because the site is a place you can obtain anything. "Peptide" in the name is descriptive of the subject matter, not an offer. There is no storefront here, no consultation, no prescription, and no clinical service of any kind. If you came looking to buy something, this is the wrong place by design: it is a reading desk, not a counter.

How we handle the science

We lead with what was measured and attribute it to the study and species. We distinguish CJC-1295's two forms — the multi-day DAC version and the roughly thirty-minute no-DAC Mod GRF (1-29) — because conflating them misreads the pharmacology. We never convert a research dose into a human recommendation, and we never present community anecdotes as clinical findings; on the effects page the two are kept visibly apart. Where the literature is precise, we are precise. Where it is silent — most of ipamorelin's human pharmacokinetics, all of the blend's — we say so plainly. Neither compound is FDA-approved, and both are prohibited for athletes under WADA Section S2; we state that wherever it is relevant rather than burying it.